References
Key articles
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer risk reduction [internet publication].Full text
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer [internet publication].Full text
Loibl S, André F, Bachelot T, et al. Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024 Feb;35(2):159-82.Full text
Morrow M, Van Zee KJ, Solin LJ, et al. Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ. J Clin Oncol. 2016 Nov 20;34(33):4040-6. [Reaffirmed 2019.]Full text Abstract
Reference articles
1. Olivotto I, Levine M; Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Clinical practice guidelines for the care and treatment of breast cancer: the management of ductal carcinoma in situ (summary of the 2001 update). CMAJ. 2001 Oct 2;165(7):912-3.Full text Abstract
2. Mannu GS, Wang Z, Broggio J, et al. Invasive breast cancer and breast cancer mortality after ductal carcinoma in situ in women attending for breast screening in England, 1988-2014: population based observational cohort study. BMJ. 2020 May 27;369:m1570.Full text Abstract
3. Mannu GS, Wang Z, Dodwell D, et al. Invasive breast cancer and breast cancer death after non-screen detected ductal carcinoma in situ from 1990 to 2018 in England: population based cohort study. BMJ. 2024 Jan 24;384:e075498.Full text Abstract
4. Hieken TJ, Cheregi J, Farolan M, et al. Predicting relapse in ductal carcinoma in situ patients: an analysis of biologic markers with long-term follow-up. Am J Surg. 2007 Oct;194(4):504-6. Abstract
5. Ginter PS, D'Alfonso TM. Current concepts in diagnosis, molecular features, and management of lobular carcinoma in situ of the breast with a discussion of morphologic variants. Arch Pathol Lab Med. 2017 Dec;141(12):1668-78.Full text Abstract
6. Leonard GD, Swain SM. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst. 2004 Jun 16;96(12):906-20.Full text Abstract
7. Shekhar MP, Tait L, Pauley RJ, et al. Comedo-ductal carcinoma in situ: a paradoxical role for programmed cell death. Cancer Biol Ther. 2008 Nov;7(11):1774-82.Full text Abstract
8. Beute BJ, Kalisher L, Hutter RV. Lobular carcinoma in situ of the breast: clinical, pathologic, and mammographic features. AJR Am J Roentgenol. 1991 Aug;157(2):257-65. Abstract
9. Wen HY, Brogi E. Lobular carcinoma in situ. Surg Pathol Clin. 2018 Mar;11(1):123-45. Abstract
10. Siegel RL, Kratzer TB, Giaquinto AN, et al. Cancer statistics, 2025. CA Cancer J Clin. 2025 Jan-Feb;75(1):10-45.Full text Abstract
11. Howlader N, Noone A, Krapcho M, et al. (eds.). SEER cancer statistics review, 1975–2008. Bethesda, MD: National Cancer Institute.Full text
12. Ryser MD, Hendrix LH, Worni M, et al. Incidence of ductal carcinoma in situ in the United States, 2000-2014. Cancer Epidemiol Biomarkers Prev. 2019 Aug;28(8):1316-23.Full text Abstract
13. Oseni TO, Zhang B, Coopey SB, et al. Twenty-five year trends in the incidence of ductal carcinoma in situ in US women. J Am Coll Surg. 2019 Jun;228(6):932-9. Abstract
14. White E, Lee CY, Kristal AR. Evaluation of the increase in breast cancer incidence in relation to mammography use. J Natl Cancer Inst. 1990 Oct 3;82(19):1546-52. Abstract
15. Camus MG, Joshi MG, Mackarem G, et al. Ductal carcinoma in situ of the male breast. Cancer. 1994 Aug 15;74(4):1289-93. Abstract
16. Nicosia L, Lissidini G, Sargenti M, et al. Ductal carcinoma in situ of the male breast: clinical radiological features and management in a cancer referral center. Breast Cancer Res Treat. 2022 Nov;196(2):371-7. Abstract
17. Virnig BA, Tuttle TM, Shamliyan T, et al. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst. 2010 Feb 3;102(3):170-8.Full text Abstract
18. Portschy PR, Marmor S, Nzara R, et al. Trends in incidence and management of lobular carcinoma in situ: a population-based analysis. Ann Surg Oncol. 2013 Oct;20(10):3240-6. Abstract
19. Dania V, Liu Y, Ademuyiwa F, et al. Associations of race and ethnicity with risk of developing invasive breast cancer after lobular carcinoma in situ. Breast Cancer Res. 2019 Nov 14;21(1):120.Full text Abstract
20. Zygogianni AG, Kyrgias G, Gennatas C, et al. Male breast carcinoma: epidemiology, risk factors and current therapeutic approaches. Asian Pac J Cancer Prev. 2012;13(1):15-9. Abstract
21. San Miguel P, Sancho M, Enriquez JL, et al. Lobular carcinoma of the male breast associated with the use of cimetidine. Virchows Arch. 1997 Mar;430(3):261-3. Abstract
22. Kerlikowske K. Epidemiology of ductal carcinoma in situ. J Natl Cancer Inst Monogr. 2010;2010(41):139-41.Full text Abstract
23. Lakhani SR. The transition from hyperplasia to invasive carcinoma of the breast. J Pathol. 1999 Feb;187(3):272-8. Abstract
24. Thorat MA, Levey PM, Jones JL, et al. Prognostic and predictive value of HER2 expression in ductal carcinoma in situ: results from the UK/ANZ DCIS randomized trial. Clin Cancer Res. 2021 Oct 1;27(19):5317-24.Full text Abstract
25. Lari SA, Kuerer HM. Biological markers in DCIS and risk of breast recurrence: a systematic review. J Cancer. 2011 May 1;2:232-61.Full text Abstract
26. Wren BG. The origin of breast cancer. Menopause. 2007 Nov-Dec;14(6):1060-8. Abstract
27. Chuba PJ, Hamre MR, Yap J, et al. Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data. J Clin Oncol. 2005 Aug 20;23(24):5534-41. Abstract
28. Mallory MA, Whiting K, Park A, et al. Synchronous and metachronous bilateral breast cancer among women with a history of lobular carcinoma in situ. Breast Cancer Res Treat. 2022 Jul;194(1):137-48. Abstract
29. King TA, Pilewskie M, Muhsen S, et al. Lobular carcinoma in situ: a 29-year longitudinal experience evaluating clinicopathologic features and breast cancer risk. J Clin Oncol. 2015 Nov 20;33(33):3945-52.Full text Abstract
30. Wazir U, Wazir A, Wells C, et al. Pleomorphic lobular carcinoma in situ: current evidence and a systemic review. Oncol Lett. 2016 Dec;12(6):4863-8.Full text Abstract
31. Shamir ER, Chen YY, Chu T, et al. Pleomorphic and florid lobular carcinoma in situ variants of the breast: a clinicopathologic study of 85 cases with and without invasive carcinoma from a single academic center. Am J Surg Pathol. 2019 Mar;43(3):399-408. Abstract
32. Peila R, Arthur R, Rohan TE. Risk factors for ductal carcinoma in situ of the breast in the UK Biobank cohort study. Cancer Epidemiol. 2020 Feb;64:101648. Abstract
33. Claus EB, Stowe M, Carter D. Breast carcinoma in situ: risk factors and screening patterns. J Natl Cancer Inst. 2001 Dec 5;93(23):1811-7.Full text Abstract
34. Kerlikowske K, Barclay J, Grady D, et al. Comparison of risk factors for ductal carcinoma in situ and invasive breast cancer. J Natl Cancer Inst. 1997 Jan 1;89(1):76-82. Abstract
35. Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017 Jun 20;317(23):2402-16.Full text Abstract
36. Sessa C, Balmaña J, Bober SL, et al. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO clinical practice guideline. Ann Oncol. 2023 Jan;34(1):33-47.Full text Abstract
37. Renaux-Petel M, Charbonnier F, Théry JC, et al. Contribution of de novo and mosaic TP53 mutations to Li-Fraumeni syndrome. J Med Genet. 2018 Mar;55(3):173-80. Abstract
38. Huang H, Couch RE, Karam R, et al. Pathogenic variants in cancer susceptibility genes predispose to ductal carcinoma in situ of the breast. Clin Cancer Res. 2025 Jan 6;31(1):130-8.Full text Abstract
39. Claus EB, Petruzella S, Matloff E, et al. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. JAMA. 2005 Feb 23;293(8):964-9.Full text Abstract
40. Birch JM, Blair V, Kelsey AM, et al. Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene. 1998 Sep 3;17(9):1061-8. Abstract
41. Brownstein MH, Wolf M, Bikowski JB. Cowden's disease: a cutaneous marker of breast cancer. Cancer. 1978 Jun;41(6):2393-8. Abstract
42. Pharoah PD, Guilford P, Caldas C, et al; International Gastric Cancer Linkage Consortium. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology. 2001 Dec;121(6):1348-53.Full text Abstract
43. Boardman LA, Thibodeau SN, Schaid DJ, et al. Increased risk for cancer in patients with the Peutz-Jeghers syndrome. Ann Intern Med. 1998 Jun 1;128(11):896-9. Abstract
44. Vasen HF. Clinical diagnosis and management of hereditary colorectal cancer syndromes. J Clin Oncol. 2000 Nov 1;18(21 Suppl):81-92S. Abstract
45. US National Library of Medicine. STK11 gene. Mar 2020 [internet publication].Full text
46. Cook B, Nayar S, Filson S, et al. The incidence of male breast cancer in Klinefelter Syndrome and its proposed mechanisms. Breast. 2024 Dec;78:103827.Full text Abstract
47. Patel AV, Press MF, Meeske K, et al. Lifetime recreational exercise activity and risk of breast carcinoma in situ. Cancer. 2003 Nov 15;98(10):2161-9. Abstract
48. Trentham-Dietz A, Newcomb PA, Storer BE, et al. Risk factors for carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev. 2000 Jul;9(7):697-703.Full text Abstract
49. Izatt L, Greenman J, Hodgson S, et al. Identification of germline missense mutations and rare allelic variants in the ATM gene in early-onset breast cancer. Genes Chromosomes Cancer. 1999 Dec;26(4):286-94. Abstract
50. FitzGerald MG, Bean JM, Hegde SR, et al. Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet. 1997 Mar;15(3):307-10. Abstract
51. Cohen AL, Ward JH. Risk reduction strategies for ductal carcinoma in situ. J Natl Compr Canc Netw. 2010 Oct;8(10):1211-7.Full text Abstract
52. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer risk reduction [internet publication].Full text
53. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis [internet publication].Full text
54. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989 Dec 20;81(24):1879-86. Abstract
55. Monticciolo DL, Newell MS, Moy L, et al. Breast cancer screening for women at higher-than-average risk: updated recommendations from the ACR. J Am Coll Radiol. 2023 Sep;20(9):902-14. Abstract
56. The American Society of Breast Surgeons. Position statement on screening mammography. 2019 [internet publication].Full text
57. Obstetrics & Gynecology. Practice bulletin number 179: breast cancer risk assessment and screening in average-risk women. Obstet Gynecol. 2017 Jul;130(1):e1-16.Full text Abstract
58. Visvanathan K, Hurley P, Bantug E, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013 Aug 10;31(23):2942-62.Full text Abstract
59. Visvanathan K, Fabian CJ, Bantug E, et al. Use of endocrine therapy for breast cancer risk reduction: ASCO clinical practice guideline update. J Clin Oncol. 2019 Nov 20;37(33):3152-65.Full text Abstract
60. Owens DK, Davidson KW, et al; US Preventive Services Task Force. Medication use to reduce risk of breast cancer: US Preventive Services Task Force recommendation statement. JAMA. 2019 Sep 3;322(9):857-67.Full text Abstract
61. Vogel VG, Costantino JP, Wickerham DL, et al; National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006 Nov;42(17):2909-13.Full text Abstract
62. Vogel VG, Costantino JP, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of tamoxifen and raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev Res (Phila). 2010 Jun;3(6):696-706.Full text Abstract
63. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: genetic/familial high-risk assessment: breast, ovarian, pancreatic, and prostate [internet publication].Full text
64. Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001 Jul 19;345(3):159-64.Full text Abstract
65. Owens DK, Davidson KW, Krist AH, et al; US Preventive Services Task Force. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US Preventive Services Task Force recommendation statement. JAMA. 2019 Aug 20;322(7):652-65.Full text Abstract
66. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer [internet publication].Full text
67. Fayanju OM, Stoll CR, Fowler S, et al. Contralateral prophylactic mastectomy after unilateral breast cancer: a systematic review and meta-analysis. Ann Surg. 2014 Dec;260(6):1000-10. Abstract
68. Hankinson SE, Colditz GA, Willett WC. Towards an integrated model for breast cancer etiology: the lifelong interplay of genes, lifestyle, and hormones. Breast Cancer Res. 2004;6(5):213-8.Full text Abstract
69. Chlebowski RT, Aragaki AK, Anderson GL, et al. Low-fat dietary pattern and breast cancer mortality in the Women's Health Initiative randomized controlled trial. J Clin Oncol. 2017 Sep 1;35(25):2919-26. Abstract
70. Smith-Warner SA, Spiegelman D, Yaun SS, et al. Alcohol and breast cancer in women: a pooled analysis of cohort studies. JAMA. 1998 Feb 18;279(7):535-40. Abstract
71. Sinclair J, McCann M, Sheldon E, et al. The acceptability of addressing alcohol consumption as a modifiable risk factor for breast cancer: a mixed method study within breast screening services and symptomatic breast clinics. BMJ Open. 2019 Jun 17;9(6):e027371.Full text Abstract
72. Cutuli B, Dilhuydy JM, De Lafontan B, et al. Ductal carcinoma in situ of the male breast: analysis of 31 cases. Eur J Cancer. 1997 Jan;33(1):35-8. Abstract
73. Monticciolo DL, Malak SF, Friedewald SM, et al. Breast cancer screening recommendations inclusive of all women at average risk: update from the ACR and Society of Breast Imaging. J Am Coll Radiol. 2021 Sep;18(9):1280-8.Full text Abstract
74. American College of Radiology. ACR appropriateness criteria®: supplemental breast cancer screening based on breast density. 2024 [internet publication].Full text
75. Chen HL, Zhou JQ, Chen Q, et al. Comparison of the sensitivity of mammography, ultrasound, magnetic resonance imaging and combinations of these imaging modalities for the detection of small (≤2 cm) breast cancer. Medicine (Baltimore). 2021 Jul 2;100(26):e26531.Full text Abstract
76. Greenwood HI, Wilmes LJ, Kelil T, et al. Role of breast MRI in the evaluation and detection of DCIS: opportunities and challenges. J Magn Reson Imaging. 2020 Sep;52(3):697-709. Abstract
77. Kuhl CK, Schrading S, Bieling HB, et al. MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study. Lancet. 2007 Aug 11;370(9586):485-92. Abstract
78. Tajima CC, de Sousa LLC, Venys GL, et al. Magnetic resonance imaging of the breast: role in the evaluation of ductal carcinoma in situ. Radiol Bras. 2019 Jan-Feb;52(1):43-7.Full text Abstract
79. Plana MN, Carreira C, Muriel A, et al. Magnetic resonance imaging in the preoperative assessment of patients with primary breast cancer: systematic review of diagnostic accuracy and meta-analysis. Eur Radiol. 2012 Jan;22(1):26-38. Abstract
80. Wright JL, Rahbar H, Obeng-Gyasi S, et al. Overcoming barriers in ductal carcinoma in situ management: from overtreatment to optimal treatment. J Clin Oncol. 2022 Jan 20;40(3):225-30.Full text Abstract
81. American Society of Breast Surgeons. Five things physicians and patients should question. Choosing Wisely, an initiative of the ABIM Foundation. 2021 [internet publication].Full text
82. Expert Panel on Breast Imaging, McDonald ES, Scheel JR, et al. ACR appropriateness criteria® imaging of invasive breast cancer. J Am Coll Radiol. 2024 Jun;21(6s):S168-202. Abstract
83. Peters NH, van Esser S, van den Bosch MA, et al. Preoperative MRI and surgical management in patients with nonpalpable breast cancer: the MONET - randomised controlled trial. Eur J Cancer. 2011 Apr;47(6):879-86. Abstract
84. Fancellu A, Turner RM, Dixon JM, et al. Meta-analysis of the effect of preoperative breast MRI on the surgical management of ductal carcinoma in situ. Br J Surg. 2015 Jul;102(8):883-93.Full text Abstract
85. van Bekkum S, Ter Braak BPM, Plaisier PW, et al. Preoperative breast MRI in management of patients with needle biopsy-proven ductal carcinoma in situ (DCIS). Eur J Surg Oncol. 2020 Oct;46(10 pt a):1854-60. Abstract
86. American College of Radiology. ACR Appropriateness Criteria® imaging of ductal carcinoma in situ (DCIS). 2024 [internet publication].Full text
87. American Society of Clinical Oncology. Ten things physicians and patients should question. Choosing Wisely, an initiative of the ABIM Foundation. 2021 [internet publication].Full text
88. Brennan ME, Turner RM, Ciatto S, et al. Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer. Radiology. 2011 Jul;260(1):119-28. Abstract
89. Caswell-Smith P, Wall M. Ductal carcinoma in situ: is core needle biopsy ever enough? J Med Imaging Radiat Oncol. 2017 Feb;61(1):29-33. Abstract
90. Bruening W, Fontanarosa J, Tipton K, et al. Systematic review: comparative effectiveness of core-needle and open surgical biopsy to diagnose breast lesions. Ann Intern Med. 2010 Feb 16;152(4):238-46. Abstract
91. Hussain M, Cunnick GH. Management of lobular carcinoma in-situ and atypical lobular hyperplasia of the breast: a review. Eur J Surg Oncol. 2011 Apr;37(4):279-89. Abstract
92. Houssami N, Ciatto S, Ellis I, et al. Underestimation of malignancy of breast core-needle biopsy: concepts and precise overall and category-specific estimates. Cancer. 2007 Feb 1;109(3):487-95.Full text Abstract
93. Breast Cancer.org. FDA says ductal lavage shouldn't be used in place of mammograms. Feb 2020 [internet publication].Full text
94. Jiwa N, Gandhewar R, Chauhan H, et al. Diagnostic accuracy of nipple aspirate fluid cytology in asymptomatic patients: a meta-analysis and systematic review of the literature. Ann Surg Oncol. 2021 Jul;28(7):3751-60.Full text Abstract
95. National Institute for Health and Care Excellence. Early and locally advanced breast cancer: diagnosis and management. Apr 2025 [internet publication].Full text
96. Park KU, Somerfield MR, Anne N, et al. Sentinel lymph node biopsy in early-stage breast cancer: ASCO guideline update. J Clin Oncol. 2025 May 10;43(14):1720-41.Full text Abstract
97. Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and progesterone receptor testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists guideline update. Arch Pathol Lab Med. 2020 May;144(5):545-63.Full text Abstract
98. Manahan ER, Kuerer HM, Sebastian M, et al. Consensus guidelines on genetic testing for hereditary breast cancer from the American Society of Breast Surgeons. Ann Surg Oncol. 2019 Oct;26(10):3025-31.Full text Abstract
99. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG committee opinion no. 727. Cascade testing: testing women for known hereditary genetic mutations associated with cancer. Obstet Gynecol. 2018 Jan;131(1):e31-4.Full text Abstract
100. Bedrosian I, Somerfield MR, Achatz MI, et al. Germline testing in patients with breast cancer: ASCO-Society of Surgical Oncology guideline. J Clin Oncol. 2024 Feb 10;42(5):584-604.Full text Abstract
101. Tung N, Ricker C, Messersmith H, et al. Selection of germline genetic testing panels in patients with cancer: ASCO guideline. J Clin Oncol. 2024 Jul 20;42(21):2599-615.Full text Abstract
102. Sessa C, Balmaña J, Bober SL, et al. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline. Ann Oncol. 2023 Jan;34(1):33-47.Full text Abstract
103. Franceschi D, Crowe J, Zollinger R, et al. Breast biopsy for calcifications in nonpalpable breast lesions. A prospective study. Arch Surg. 1990 Feb;125(2):170-3. Abstract
104. Silverstein MJ. The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast. Am J Surg. 2003 Oct;186(4):337-43. Abstract
105. Claus EB. Risk models used to counsel women for breast and ovarian cancer: a guide for clinicians. Fam Cancer. 2001;1(3-4):197-206. Abstract
106. Narod SA, Iqbal J, Giannakeas V, et al. Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol. 2015 Oct;1(7):888-96.Full text Abstract
107. Xia LY, Xu WY, Hu QL. Survival outcomes after breast-conserving surgery plus radiotherapy compared with mastectomy in breast ductal carcinoma in situ with microinvasion. Sci Rep. 2022 Nov 22;12(1):20132.Full text Abstract
108. Loibl S, André F, Bachelot T, et al. Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024 Feb;35(2):159-82.Full text
109. Morrow M, Van Zee KJ, Solin LJ, et al. Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ. J Clin Oncol. 2016 Nov 20;34(33):4040-6. [Reaffirmed 2019.]Full text Abstract
110. McCormick B, Winter K, Hudis C, et al. RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol. 2015 Mar 1;33(7):709-15.Full text Abstract
111. McCormick B, Winter KA, Woodward W, et al. Randomized phase III trial evaluating radiation following surgical excision for good-risk ductal carcinoma in situ: long-term report from NRG Oncology/RTOG 9804. J Clin Oncol. 2021 Nov 10;39(32):3574-82. Abstract
112. Wapnir IL, Dignam JJ, Fisher B, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011 Mar 16;103(6):478-88.Full text Abstract
113. Doyle S, Lips EH, Marcus E, et al. Deep learning for predicting invasive recurrence of ductal carcinoma in situ: leveraging histopathology images and clinical features. EBioMedicine. 2025 Jun;116:105750. Abstract
114. Rakovitch E, Nofech-Mozes S, Hanna W, et al. Multigene expression assay and benefit of radiotherapy after breast conservation in ductal carcinoma in situ. J Natl Cancer Inst. 2017 Apr 1;109(4):djw256.Full text Abstract
115. Solin LJ, Gray R, Baehner FL, et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2013 May 15;105(10):701-10.Full text Abstract
116. van Seijen M, Lips EH, Thompson AM, et al. Ductal carcinoma in situ: to treat or not to treat, that is the question. Br J Cancer. 2019 Aug;121(4):285-92.Full text Abstract
117. Armani A, Douglas S, Kulkarni S, et al. Controversial areas in axillary staging: are we following the guidelines? Ann Surg Oncol. 2021 Oct;28(10):5580-7.Full text Abstract
118. Nicholson S, Hanby A, Clements K, et al. Variations in the management of the axilla in screen-detected ductal carcinoma in situ: evidence from the UK NHS breast screening programme audit of screen detected DCIS. Eur J Surg Oncol. 2015 Jan;41(1):86-93. Abstract
119. Chen Q, Campbell I, Elwood M, et al. Outcomes from low-risk ductal carcinoma in situ: a systematic review and meta-analysis. Breast Cancer Res Treat. 2024 Nov;208(2):237-51.Full text Abstract
120. Stuart KE, Houssami N, Taylor R, et al. Long-term outcomes of ductal carcinoma in situ of the breast: a systematic review, meta-analysis and meta-regression analysis. BMC Cancer. 2015 Nov 10;15:890.Full text Abstract
121. Giannakeas V, Sopik V, Narod SA. Association of radiotherapy with survival in women treated for ductal carcinoma in situ with lumpectomy or mastectomy. JAMA Netw Open. 2018 Aug 3;1(4):e181100.Full text Abstract
122. Chua BH, Link EK, Kunkler IH, et al. Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study. Lancet. 2022 Aug 6;400(10350):431-40. Abstract
123. Shaitelman SF, Anderson BM, Arthur DW, et al. Partial breast irradiation for patients with early-stage invasive breast cancer or ductal carcinoma in situ: an ASTRO clinical practice guideline. Pract Radiat Oncol. 2024 Mar-Apr;14(2):112-32.Full text Abstract
124. Haussmann J, Budach W, Corradini S, et al. Comparison of adverse events in partial- or whole breast radiotherapy: investigation of cosmesis, toxicities and quality of life in a meta-analysis of randomized trials. Radiat Oncol. 2023 Nov 2;18(1):181.Full text Abstract
125. Whelan TJ, Julian JA, Berrang TS, et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet. 2019 Dec 14;394(10215):2165-72. Abstract
126. Coles CE, Griffin CL, Kirby AM, et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet. 2017 Sep 9;390(10099):1048-60.Full text Abstract
127. Strnad V, Polgár C, Ott OJ, et al. Accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy compared with whole-breast irradiation with boost for early breast cancer: 10-year results of a GEC-ESTRO randomised, phase 3, non-inferiority trial. Lancet Oncol. 2023 Mar;24(3):262-72. Abstract
128. Offersen BV, Alsner J, Nielsen HM, et al. Partial breast irradiation versus whole breast irradiation for early breast cancer patients in a randomized phase III trial: the Danish breast cancer group partial breast irradiation Trial. J Clin Oncol. 2022 Dec 20;40(36):4189-97. Abstract
129. Meattini I, Marrazzo L, Saieva C, et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-florence trial. J Clin Oncol. 2020 Dec 10;38(35):4175-83. Abstract
130. Polgár C, Major T, Takácsi-Nagy Z, et al. Breast-conserving surgery followed by partial or whole breast irradiation: twenty-year results of a phase 3 clinical study. Int J Radiat Oncol Biol Phys. 2021 Mar 15;109(4):998-1006. Abstract
131. Shumway DA, Corbin KS, Farah MH, et al. Partial breast irradiation compared with whole breast irradiation: a systematic review and meta-analysis. J Natl Cancer Inst. 2023 Sep 7;115(9):1011-9.Full text Abstract
132. Vicini FA, Cecchini RS, White JR, et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet. 2019 Dec 14;394(10215):2155-64.Full text Abstract
133. Orecchia R, Veronesi U, Maisonneuve P, et al. Intraoperative irradiation for early breast cancer (ELIOT): long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalence trial. Lancet Oncol. 2021 May;22(5):597-608. Abstract
134. National Institute for Health and Care Excellence. Intrabeam radiotherapy system for adjuvant treatment of early breast cancer. Jan 2018 [internet publication].Full text
135. Vaidya JS, Wenz F, Bulsara M, et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet. 2014 Feb 15;383(9917):603-13.Full text Abstract
136. Franceschini D, Loi M, Chiola I, et al. Preliminary results of a randomized study on postmenopausal women with early stage breast cancer: adjuvant hypofractionated whole breast irradiation versus accelerated partial breast irradiation (HYPAB Trial). Clin Breast Cancer. 2021 Jun;21(3):231-8. Abstract
137. Polgár C, Ott OJ, Hildebrandt G, et al. Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2017 Feb;18(2):259-68. Abstract
138. Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013 Mar 14;368(11):987-98.Full text Abstract
139. Shah C, Al-Hilli Z, Vicini F. Advances in breast cancer radiotherapy: implications for current and future practice. JCO Oncol Pract. 2021 Dec;17(12):697-706.Full text Abstract
140. Pappo I, Wasserman I, Halevy A. Ductal carcinoma in situ of the breast in men: a review. Clin Breast Cancer. 2005 Oct;6(4):310-4. Abstract
141. Sundara Rajan S, Verma R, Shaaban AM, et al. Palpable ductal carcinoma in situ: analysis of radiological and histological features of a large series with 5-year follow-up. Clin Breast Cancer. 2013 Dec;13(6):486-91. Abstract
142. O'Flynn EA, Morel JC, Gonzalez J, et al. Prediction of the presence of invasive disease from the measurement of extent of malignant microcalcification on mammography and ductal carcinoma in situ grade at core biopsy. Clin Radiol. 2009 Feb;64(2):178-83.Full text Abstract
143. Kurniawan ED, Rose A, Mou A, et al. Risk factors for invasive breast cancer when core needle biopsy shows ductal carcinoma in situ. Arch Surg. 2010 Nov;145(11):1098-104.Full text Abstract
144. Moran CJ, Kell MR, Flanagan FL, et al. Role of sentinel lymph node biopsy in high-risk ductal carcinoma in situ patients. Am J Surg. 2007 Aug;194(2):172-5. Abstract
145. Davey MG, O'Flaherty C, Cleere EF, et al. Sentinel lymph node biopsy in patients with ductal carcinoma in situ: systematic review and meta-analysis. BJS Open. 2022 Mar 8;6(2):zrac022.Full text Abstract
146. El Hage Chehade H, Headon H, Wazir U, et al. Is sentinel lymph node biopsy indicated in patients with a diagnosis of ductal carcinoma in situ? a systematic literature review and meta-analysis. Am J Surg. 2017 Jan;213(1):171-80. Abstract
147. Godat LN, Horton JK, Shen P, et al. Recurrence after mastectomy for ductal carcinoma in situ. Am Surg. 2009 Jul;75(7):592-5; discussion 595-7. Abstract
148. Hwang ES. The impact of surgery on ductal carcinoma in situ outcomes: the use of mastectomy. J Natl Cancer Inst Monogr. 2010;2010(41):197-9.Full text Abstract
149. Clements K, Dodwell D, Lawrence G, et al. Radiotherapy after mastectomy for screen-detected ductal carcinoma in situ. Eur J Surg Oncol. 2015 Oct;41(10):1406-10. Abstract
150. Staley H, McCallum I, Bruce J. Postoperative tamoxifen for ductal carcinoma in situ. Cochrane Database Syst Rev. 2012 Oct 17;(10):CD007847.Full text Abstract
151. Margolese RG, Cecchini RS, Julian TB, et al. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet. 2016 Feb 27;387(10021):849-56.Full text Abstract
152. Biganzoli L, Battisti NML, Wildiers H, et al. Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG). Lancet Oncol. 2021 Jul;22(7):e327-40. Abstract
153. Petrelli F, Barni S. Tamoxifen added to radiotherapy and surgery for the treatment of ductal carcinoma in situ of the breast: a meta-analysis of 2 randomized trials. Radiother Oncol. 2011 Aug;100(2):195-9. Abstract
154. Goss PE, Ingle JN, Alés-Martínez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011 Jun 23;364(25):2381-91.Full text Abstract
155. Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet. 2014 Mar 22;383(9922):1041-8.Full text Abstract
156. Visser LL, Groen EJ, van Leeuwen FE, et al. Predictors of an invasive breast cancer recurrence after DCIS: a systematic review and meta-analyses. Cancer Epidemiol Biomarkers Prev. 2019 May;28(5):835-45.Full text Abstract
157. Rowell NP. Are mastectomy resection margins of clinical relevance? A systematic review. Breast. 2010 Feb;19(1):14-22.Full text Abstract
158. Rosso S, Gondos A, Zanetti R, et al; EUNICE Survival Working Group. Up-to-date estimates of breast cancer survival for the years 2000-2004 in 11 European countries: the role of screening and a comparison with data from the United States. Eur J Cancer. 2010 Dec;46(18):3351-7. Abstract
159. Cocquyt V, Van Belle S. Lobular carcinoma in situ and invasive lobular cancer of the breast. Curr Opin Obstet Gynecol. 2005 Feb;17(1):55-60. Abstract
160. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88. Abstract
161. Davies C, Pan H, Godwin J, et al; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013 Mar 9;381(9869):805-16.Full text Abstract
162. Kelley BP, Valero V, Yi M, et al. Tamoxifen increases the risk of microvascular flap complications in patients undergoing microvascular breast reconstruction. Plast Reconstr Surg. 2012 Feb;129(2):305-14.Full text Abstract
163. Khosrow-Khavar F, Filion KB, Bouganim N, et al. Aromatase inhibitors and the risk of cardiovascular outcomes in women with breast cancer: a population-based cohort study. Circulation. 2020 Feb 18;141(7):549-59.Full text Abstract
164. Ligibel JA, Bohlke K, May AM, et al. Exercise, diet, and weight management during cancer treatment: ASCO guideline. J Clin Oncol. 2022 Aug 1;40(22):2491-507.Full text Abstract
165. Rock CL, Thomson CA, Sullivan KR, et al. American Cancer Society nutrition and physical activity guideline for cancer survivors. CA Cancer J Clin. 2022 May;72(3):230-62.Full text Abstract
166. Luo J, Cochrane BB, Wactawski-Wende J, et al. Effects of menopausal hormone therapy on ductal carcinoma in situ of the breast. Breast Cancer Res Treat. 2013 Feb;137(3):915-25. Abstract
167. Poggio F, Del Mastro L, Bruzzone M, et al. Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis. Breast Cancer Res Treat. 2022 Jan;191(2):269-75. Abstract
168. Martino S, Cauley JA, Barrett-Connor E, et al; CORE Investigators. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004 Dec 1;96(23):1751-61.Full text Abstract
169. Forbes JF, Sestak I, Howell A, et al. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Lancet. 2016 Feb 27;387(10021):866-73.Full text Abstract
Use of this content is subject to our disclaimer